Recruiting

Observational Study

Sponsor:

Eko Devices, Inc.

Code:

NCT07087613

Conditions

Hypertension, Pulmonary

Heart Failure With Reduced Ejection Fraction

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Eko CORE 500 Digital Stethoscope

Study Details

Brief summary:

This is a prospective, observational study evaluating whether heart sounds (phonocardiograms) and three-lead electrocardiograms (ECGs) recorded using the Eko CORE 500 digital stethoscope can help detect pulmonary hypertension (PH) and low left ventricular ejection fraction (EF ≤ 40%). PH is a condition characterized by high blood pressure in the pulmonary arteries, which can lead to heart failure and carries significant risks if undiagnosed. Low EF, which indicates reduced pumping ability of the heart, is also associated with increased risk of severe cardiac events but can remain undetected because patients often have no symptoms or only nonspecific symptoms.

In this study, adults undergoing clinically indicated echocardiograms or right heart catheterization at outpatient sites will be invited to participate. Participants will complete a single study session lasting about 20 minutes, during which heart sounds and a three-lead ECG will be collected using the Eko CORE 500 device. If participants have had a clinical 12-lead ECG within 30 days of their echocardiogram or right heart catheterization, those data may also be used for analysis. A clinically indicated echocardiogram or right heart catheterization (RHC) performed within seven days before or after the Eko CORE 500 recording will serve as the reference standard to confirm the presence or absence of PH and low EF.

Up to 3,850 participants may be enrolled across multiple sites to ensure that approximately 3,500 complete the study. The data collected will be used to develop and validate artificial intelligence (AI) algorithms that aim to detect PH and identify low EF, potentially enabling earlier and simpler screening for these conditions in clinical practice.

Conditions

Hypertension, Pulmonary

Heart Failure With Reduced Ejection Fraction

Study ID

NCT07087613

Start date

Jun 15, 2025

Status verified date

Jun, 2026

Completion date

May 31, 2027

Anticipated

Primary completion date

May 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults aged 18 years and older
  • Able and willing to provide informed consent
  • Completed a clinical echocardiogram or right heart catheterization within 7 days before or after study procedures

Exclusion Criteria:

  • Unwilling or unable to provide informed consent
  • Patients who are hospitalized
  • Patients undergoing echocardiography with a limited echocardiogram (does not apply to patients undergoing right heart catheterization)

Study Design

Enrollment

3850 participants

Anticipated

Interventions and Outcome Measures

Arms

All Participants

Adults aged 18 years and older undergoing clinically indicated transthoracic echocardiography or right heart catheterization in an outpatient setting. Participants will have phonocardiogram (PCG) and 3-lead ECG recordings collected using the Eko CORE 500 digital stethoscope. Data will be used to develop and validate artificial intelligence algorithms to detect pulmonary hypertension and low left ventricular ejection fraction.

Interventions

Eko CORE 500 Digital Stethoscope

The FDA-cleared Eko CORE 500 digital stethoscope is used to collect phonocardiogram (PCG) and three-lead ECG recordings from participants. This observational study uses these recordings to develop and validate artificial intelligence algorithms to detect pulmonary hypertension and low left ventricular ejection fraction. No modifications to the device or device functionality are being tested.

Primary outcome measure

  • Sensitivity and specificity of the deep-learning algorithm for detecting pulmonary hypertension (PH) [ Time Frame: Up to 24 months ]

Central Contacts and Locations

Central contacts

Locations

Prairie Cardiovascular

Recruiting

O'Fallon, Illinois, United States, 62269

Contacts

Principal Investigator:

Scott Marrus, MD

Prairie Education & Research Cooperative

Recruiting

Springfield, Illinois, United States, 62769

Contacts

Principal Investigator:

Scott Marrus, MD

St Johns Hospital, Springfield

Recruiting

Springfield, Illinois, United States, 62769

Contacts

Principal Investigator:

Scott Marrus, MD

Sentara Norfolk General Hospital

Recruiting

Norfolk, Virginia, United States, 23501

Contacts

Principal Investigator:

Raymond Benza, MD

More Information

Sponsor

Eko Devices, Inc.

Last update posted

Jun 18, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-02. This information was provided to ClinicalTrials.gov by Eko Devices, Inc. on 2026-06-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.